“Genetic Polymorphism in CYP2D6 and its Association with the Safety and Efficacy of Fluvoxamine in Patients with Major Depressive Disorder ”, Precis. Med. Com., vol. 3, no. 1, pp. 43–49, Jun. 2023, doi: 10.55627/pmc.003.01.0301.